Biomatter
Agent43 out of 100, Above median. Agent Readiness. Open the scores section.Agent Readiness: 43/100. Above median. Measured by StartupHub.ai. Median 41.Trust62 out of 100, Above median. Data Trust. Open the scores section.Data Trust: 62/100. Above median. Measured by StartupHub.ai. Median 61.Custom enzyme design company
About
Custom enzyme design company. Biomatter is a custom enzyme design company whose work is incorporated into molecular biology products, including enzymes used to convert RNA into DNA for research and mRNA applications.
Key facts
- Website
- biomatter.ai
- Headquarters
- Vilnius, Lithuania
- Total funding
- $26M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 12 Nov 2026 | Series A | $18M | Astanor Ventures |
| 5 Aug 2024 | Seed | $7M | UVC Partners, Inventure |
| 11 Jan 2021 | Seed | $540K | Practica Capital |
Tech stack
Detected on biomatter.ai, last scanned 13 Nov 2026. Run your own scan
- Analytics
- Google Analytics 4, Google Tag Manager
- CMS / Builders
- WordPress
- Email provider
- Google Workspace
- Hiring platform
- Teamtailor
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Biomatter trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Biomatter is 62 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Biomatter raised?
Biomatter has raised a total of $26M in funding. The most recent round on record is Series A.
SEC filings, insider activity, nonprofit links and pay benchmarks for Biomatter:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
